Novartis inks $1.7 billion drug target agreement with UK’s Relation Therapeutics (NVS:NYSE)
Novartis AG (NVS) to pay UK biotech Relation Therapeutics Ltd. as much as $1.7 billion to help find drug targets to treat allergic diseases. The deal aims to combine Novartis’s (NVS) expertise in immuno-dermatology with the British firm’s drug discovery ...